Key Takeaways
Tirzepatide and semaglutide may be FSA or HSA eligible in 2026 when a licensed provider prescribes them to treat a diagnosed medical condition. The key is not just the medication itself. It is the medical reason behind the prescription and the documentation that supports it.
Many claims are denied because the paperwork is incomplete or unclear. If your diagnosis, prescription, receipt, or letter of medical necessity does not match what your FSA or HSA administrator needs, your claim may be rejected even if the treatment could qualify.
This guide explains what qualifies, what commonly gets denied, how to use your FSA or HSA for tirzepatide and semaglutide, and what kind of documentation can help support your claim.
Before we get into the details, here is the short answer: eligibility depends on medical necessity and documentation, not just the brand name or formulation.
| Medication | HSA Eligible? | FSA Eligible? | LMN Often Needed? | Notes |
| Compounded semaglutide | Yes | Yes | Sometimes | For a diagnosed condition. The InjectCo program documents this. |
| Compounded tirzepatide | Yes | Yes | Sometimes | Same IRS standard applies. |
| Wegovy (brand semaglutide) | Yes | Yes | Often | Weight loss use may require an LMN. |
| Ozempic (brand semaglutide) | Yes | Yes | Rarely | Diabetes use is most straightforward. |
| Zepbound (brand tirzepatide) | Yes | Yes | Often | Weight loss use may require an LMN. |
| Mounjaro (brand tirzepatide) | Yes | Yes | Rarely | Diabetes use is most straightforward. |
Semaglutide and tirzepatide may be HSA and FSA-eligible when a licensed healthcare provider prescribes them to treat a diagnosed medical condition.
The key is medical necessity. Your FSA or HSA administrator will usually look for a clear connection between the prescription and a qualifying diagnosis, such as obesity, diabetes, or another provider-documented condition.
This applies whether the medication is brand-name or compounded, as long as the prescription is tied to a legitimate diagnosis and supported by the right documentation. The claim is less about the medication name and more about why it was prescribed.
The short answer to the most common questions:
| Question | Answer |
| Is tirzepatide FSA eligible? | Eligible with a valid prescription for a diagnosed condition |
| Is semaglutide FSA eligible? | Eligible with a valid prescription for a diagnosed condition |
| Is tirzepatide HSA eligible? | Eligible under the same IRS standard |
| Do I need a Letter of Medical Necessity? | Sometimes. It depends on your plan and diagnosis. |
| Does brand vs. compounded matter? | No. IRS eligibility is based on medical necessity, not brand. |
The key phrase in all of this is “diagnosed medical condition.” If the prescription exists purely for cosmetic weight loss with no documented diagnosis, most FSA administrators will deny the claim.
Weight loss medications may qualify for HSA or FSA use when they are prescribed to treat a diagnosed medical condition. The IRS standard focuses on expenses used for the diagnosis, treatment, mitigation, cure, or prevention of disease.
For semaglutide and tirzepatide, the strongest qualifying cases usually involve a documented diagnosis, such as:
The same medication can get approved for one patient and denied for another. The difference is usually the documentation.
If a prescription only says “weight management,” an FSA or HSA administrator may treat it as a general wellness expense and deny the claim. If the record includes a diagnosis, BMI, related condition, and treatment purpose, the claim is much stronger.
The medication is only one part of the review. The bigger question is whether your provider documented why you need it medically.
Qualifying is only the first step. To avoid delays or denials, make sure your prescription, diagnosis, and payment records all support the same medical purpose.
Start with a proper medical evaluation. Your provider needs to assess your health history, BMI, existing conditions, and any contraindications before prescribing. This evaluation creates the documentation trail your FSA or HSA administrator needs if they review the claim.
Ask your provider directly: “Can you document my diagnosis and the medical necessity for this prescription?” Most providers handle this automatically. Asking upfront avoids a follow-up call later.
Your prescription should connect to a documented medical condition, such as type 2 diabetes, obesity, insulin resistance, prediabetes, or overweight with a related condition.
This matters because weight loss medications can be reviewed as dual-purpose expenses. A prescription that only says “weight management” may be harder to defend than one tied to a specific diagnosis and treatment plan.
Not every plan requires one, but getting one proactively is worth it for GLP-1 medications. An LMN is a signed letter from your provider that states:
Keep a copy. Your FSA administrator can request it at any point, including months after your purchase.
You may be able to use your HSA or FSA card at the pharmacy or provider checkout. If the card works, still keep your receipt and documentation in case the claim is reviewed later.
If your card is declined, it does not always mean the expense is ineligible. Sometimes the payment system does not recognize the provider or transaction type. In that case, pay out of pocket and submit a reimbursement claim.
If you pay out of pocket, submit your claim through your HSA or FSA administrator’s portal. You will usually need an itemized receipt showing the medication name, date of purchase, provider or pharmacy, and total cost.
Some administrators may also ask for your prescription or Letter of Medical Necessity.
Keep all three on file: your prescription, itemized receipt, and provider documentation.
This is the section most guides skip. Knowing you qualify does not help if your paperwork fails. Here are the exact reasons FSA claims for semaglutide and tirzepatide get rejected, and how to fix each one before it happens.
This is the most common failure point. The prescription exists, but it does not reference a specific diagnosis. Prescription language like “weight management” or “patient requested” gives an FSA administrator grounds to deny the claim. The fix is simple: ask your provider to document the specific diagnosis, whether obesity, type 2 diabetes, or insulin resistance, with the corresponding ICD-10 code before you fill the prescription.
If the clinical notes frame the treatment as improving appearance, energy, or general wellness without connecting it to a diagnosed condition, the claim fails. FSA eligibility requires medical necessity. A provider note that says “patient wishes to lose 20 pounds before a wedding” with no diagnosis code is not a medical claim. A note that says “obese patient, BMI 36.1, prescribed for treatment of obesity-related hypertension and prediabetes” is.
Some FSA administrators require a Letter of Medical Necessity for weight-related prescriptions regardless of the diagnosis. If yours does and you do not have one, the claim fails even when everything else is correct. Call your plan administrator before submitting and ask directly: does your plan require an LMN for GLP-1 medications?
If your provider is not set up to process HSA/FSA card transactions, the card will be declined at checkout. This is not a denial of eligibility. It is a payment network issue. The fix is to pay out of pocket and submit for reimbursement with the itemized receipt.
If you use your HSA for a non-qualifying expense, the withdrawal becomes taxable income. If you are under 65, you also pay a 20 percent penalty on top of that. This is why confirming eligibility and keeping documentation before you pay matters more than sorting it out after.
If your claim was denied, the appeal path is usually straightforward:
Both medications qualify under the same IRS standard, but there are practical differences in how providers typically document them.
| Factor | Semaglutide | Tirzepatide |
| FDA approval for weight loss | Wegovy (injectable), oral Wegovy | Zepbound |
| FDA approval for diabetes | Ozempic | Mounjaro |
| Clearest approval path | Type 2 diabetes | Type 2 diabetes |
| Weight loss use documentation | LMN often recommended | LMN often recommended |
| Compounded version eligible? | Yes, same IRS standard | Yes, same IRS standard |
| Primary risk for denial | Vague prescription language | Vague prescription language |
For both medications, a diabetes diagnosis produces the cleanest approval path with the least documentation friction. A weight loss diagnosis is fully valid but may require an LMN depending on your plan.
If your provider prescribes either medication off-label for a condition like PCOS or insulin resistance, eligibility is still possible. Ask your provider to document the clinical rationale and get an LMN. The more specific the paperwork, the stronger the claim.
If you are searching for a program already set up to support FSA and HSA reimbursement, the documentation process matters as much as the medication itself. Not all programs are built the same way.
| Program Type | FSA/HSA Eligible? | LMN Support? | Licensed Oversight? |
| InjectCo compounded semaglutide program | Yes | Yes, provider documents diagnosis from day one | Yes, licensed RNs and physician oversight |
| InjectCo compounded tirzepatide program | Yes | Yes, same documentation protocol | Yes |
| Generic telehealth (evaluation + compounded Rx) | Yes, if properly documented | Varies by provider | Varies |
| Brand-name GLP-1 via retail pharmacy | Yes, if properly documented | Patient must request | Prescribing provider |
| Wellness/weight loss app without Rx | No | N/A | No |
| OTC supplements marketed as GLP-1 alternatives | No | N/A | No |
InjectCo’s medically supervised semaglutide program and tirzepatide program include a clinical evaluation, licensed provider review, and documentation of your diagnosis and treatment rationale from the first consultation. Every patient receives the paperwork foundation that FSA and HSA administrators look for.
In many cases, you can. Bariatric surgery, including gastric bypass, sleeve gastrectomy, and similar procedures, qualifies as an HSA and FSA expense when performed to treat a diagnosed condition such as obesity, type 2 diabetes, or severe cardiovascular disease.
The same documentation principle applies. The surgery must be medically necessary, not elective for cosmetic reasons. Your provider needs to document the diagnosis and the clinical rationale for the procedure. Most bariatric practices handle this documentation routinely because their patients rely on insurance and pre-tax accounts to cover costs.
GLP-1 medications get most of the attention, but several related expenses can also qualify. Here is what else you may be able to use pre-tax dollars on:
This section catches people off guard because some of these feel like they should qualify.
Telehealth programs can be eligible medical expenses when they include a real medical evaluation by a licensed provider and result in a prescription tied to a diagnosed condition. The fact that the consultation happens virtually does not change the IRS eligibility status. What matters is what is documented, not where the consultation took place.
A few practical notes for using HSA/FSA with an online GLP-1 program:
If you plan to use pre-tax funds for your GLP-1 program, knowing your limits helps you plan.
For 2026, the FSA contribution limit is $3,400, or about $283 per month.
For HSAs in 2026, you can contribute up to $4,400 with a high-deductible health plan for individual coverage, or $8,750 for family coverage. At age 55, individuals can contribute an additional $1,000.
For FSA plans that allow carryover, the maximum carryover amount increased to $680 in 2026.
At $249 per month for a compounded semaglutide or tirzepatide program, your annual cost is roughly $2,988. That sits comfortably within both the HSA and FSA annual limits, so you can fund your entire program with pre-tax dollars if your documentation supports it.
The tax math is meaningful. On a $3,000 annual program, using pre-tax HSA or FSA funds saves you 20 to 35 percent depending on your tax bracket, between $600 and $1,050 back in your pocket just from using the right payment method.
Here is the practical checklist before you try to pay with your HSA or FSA card.
If you want to use HSA or FSA funds for semaglutide or tirzepatide, documentation matters. A medically supervised program can help make sure your evaluation, diagnosis, prescription, and treatment plan are properly recorded.
InjectCo’s compounded semaglutide program starts at $249 per month and includes a secure online medical evaluation, licensed provider review, and ongoing monitoring by registered nurses and physician assistants under physician oversight. Every patient receives a clinical assessment, so the medical reason for treatment is documented from the start.
You can also ask about InjectCo’s tirzepatide program or BriteBody weight loss program during your consultation. A licensed provider can review your goals, health history, and eligibility before recommending the option that fits your situation.
Book your free virtual consultation at InjectCo or call (817) 533-7676 to get started.
Frequently Asked Questions
Tirzepatide is HSA eligible when a licensed provider prescribes it for a diagnosed condition like obesity, type 2 diabetes, or overweight with a comorbidity. The IRS eligibility standard applies to both brand-name and compounded versions.
Semaglutide qualifies as an FSA expense when prescribed for a diagnosed medical condition. This applies to compounded semaglutide and brand-name versions alike. The IRS requirement is medical necessity, not brand name.
Tirzepatide is FSA eligible when a licensed provider prescribes it to treat a diagnosed condition. The IRS requires medical necessity, not just a general desire to lose weight. A proper evaluation and documented diagnosis are the foundation of any eligible claim.
Weight loss injections qualify when they are part of a physician-supervised program addressing a diagnosed condition such as obesity or type 2 diabetes. Medical necessity documentation from your provider is required.
Not always. For diabetes medications, the prescription often suffices. For weight loss use, some FSA administrators require an LMN. Getting one proactively, regardless of whether your plan requires it, significantly reduces the chance of a denied claim.
Medical weight loss programs qualify when they are physician-supervised and address a diagnosed condition. Program fees for medically supervised plans generally qualify. General wellness memberships without a medical diagnosis do not.
Compounded tirzepatide qualifies under the same standard as brand-name versions. The IRS eligibility requirement is tied to the prescription and medical necessity, not the brand or formulation.
The withdrawal becomes taxable income. If you are under 65, you also pay a 20 percent penalty in addition to the income tax. This is why confirming eligibility and keeping documentation matters upfront.
For 2026, the FSA contribution limit is $3,400 per year, or about $283 per month.
In 2026, the HSA contribution limit is $4,400 for individual coverage and $8,750 for family coverage. Those 55 and older can add an additional $1,000 catch-up contribution.
Tirzepatide prescribed for weight loss is FSA eligible when your provider documents obesity or overweight with a comorbidity as the diagnosed condition. The diagnosis language in the prescription is the key, not the intended outcome. A Letter of Medical Necessity helps prevent denial for weight loss prescriptions.
Any prescription weight loss medication can qualify as an FSA expense when a licensed provider prescribes it to treat a diagnosed condition. This includes compounded semaglutide, compounded tirzepatide, Wegovy, Ozempic, Zepbound, and Mounjaro. The IRS standard applies to the prescription and diagnosis, not the specific medication.
Zepbound is FSA eligible when prescribed for a diagnosed condition such as obesity, overweight with a comorbidity, or type 2 diabetes. For weight loss use, a Letter of Medical Necessity is often recommended to prevent claim denial. For diabetes use, the prescription typically suffices.
Compounded GLP-1 programs qualify for FSA and HSA coverage when they include a licensed medical evaluation, a prescription tied to a diagnosed condition, and proper documentation. Programs that build the clinical record from the first consultation, including diagnosis documentation and treatment rationale, give you the strongest foundation for approval. InjectCo’s medically supervised semaglutide and tirzepatide programs are structured to support this from day one.
A Letter of Medical Necessity (LMN) is a signed letter from your licensed healthcare provider that states your diagnosis with its ICD-10 code, why the medication is medically necessary for your condition, and the expected treatment plan and duration. It is not always required, but having one on file significantly reduces the risk of a denied FSA or HSA claim for weight loss medications.
Online GLP-1 programs are eligible for HSA payment when the program includes a real medical evaluation by a licensed provider and the prescription is tied to a diagnosed condition. Whether the HSA card works at checkout depends on how the provider processes payments. If the card is declined at checkout, pay out of pocket and submit an itemized receipt for reimbursement.
